Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiosurgery | 58 | 2019 | 322 | 16.500 |
Why?
|
Brain Neoplasms | 69 | 2019 | 587 | 16.390 |
Why?
|
Glioblastoma | 12 | 2018 | 143 | 3.610 |
Why?
|
Trigeminal Neuralgia | 8 | 2019 | 33 | 2.870 |
Why?
|
Cranial Irradiation | 12 | 2019 | 84 | 2.760 |
Why?
|
Middle Aged | 78 | 2019 | 10829 | 2.580 |
Why?
|
Treatment Outcome | 44 | 2019 | 3099 | 2.550 |
Why?
|
Salvage Therapy | 15 | 2019 | 118 | 2.450 |
Why?
|
Meningioma | 9 | 2017 | 51 | 2.450 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2018 | 337 | 2.410 |
Why?
|
Retrospective Studies | 46 | 2019 | 3111 | 2.370 |
Why?
|
Glioma | 11 | 2019 | 133 | 2.340 |
Why?
|
Radiotherapy | 7 | 2019 | 74 | 2.330 |
Why?
|
Aged | 61 | 2019 | 9487 | 2.230 |
Why?
|
Lung Neoplasms | 13 | 2019 | 384 | 2.170 |
Why?
|
Female | 85 | 2019 | 18164 | 2.080 |
Why?
|
Humans | 111 | 2019 | 29093 | 1.990 |
Why?
|
Male | 78 | 2019 | 17807 | 1.960 |
Why?
|
Aged, 80 and over | 34 | 2019 | 3717 | 1.820 |
Why?
|
Adult | 55 | 2019 | 8420 | 1.810 |
Why?
|
Melanoma | 8 | 2017 | 148 | 1.600 |
Why?
|
Meningeal Neoplasms | 7 | 2017 | 46 | 1.600 |
Why?
|
Follow-Up Studies | 27 | 2019 | 2108 | 1.560 |
Why?
|
Multiple Sclerosis | 3 | 2019 | 43 | 1.520 |
Why?
|
Nomograms | 4 | 2017 | 30 | 1.250 |
Why?
|
Prognosis | 11 | 2019 | 1362 | 1.060 |
Why?
|
Breast Neoplasms | 10 | 2019 | 666 | 1.030 |
Why?
|
Antineoplastic Agents, Alkylating | 4 | 2018 | 40 | 1.000 |
Why?
|
Radiotherapy Dosage | 13 | 2017 | 98 | 0.990 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2019 | 93 | 0.980 |
Why?
|
Survival Analysis | 12 | 2019 | 440 | 0.970 |
Why?
|
Adenocarcinoma | 4 | 2019 | 301 | 0.970 |
Why?
|
Survival Rate | 11 | 2019 | 795 | 0.960 |
Why?
|
Postoperative Complications | 6 | 2019 | 670 | 0.940 |
Why?
|
Cognition Disorders | 4 | 2015 | 390 | 0.930 |
Why?
|
Radiation Injuries | 7 | 2016 | 67 | 0.900 |
Why?
|
Genomics | 3 | 2018 | 82 | 0.900 |
Why?
|
Neoplasms | 4 | 2018 | 610 | 0.890 |
Why?
|
Magnetic Resonance Imaging | 14 | 2019 | 1218 | 0.880 |
Why?
|
Neoplasm Metastasis | 5 | 2019 | 199 | 0.840 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2017 | 68 | 0.760 |
Why?
|
Astrocytoma | 2 | 2018 | 30 | 0.750 |
Why?
|
Young Adult | 17 | 2018 | 2402 | 0.750 |
Why?
|
Disease Progression | 6 | 2019 | 572 | 0.700 |
Why?
|
Pineal Gland | 1 | 2018 | 3 | 0.680 |
Why?
|
Combined Modality Therapy | 9 | 2018 | 525 | 0.680 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 88 | 0.660 |
Why?
|
Treatment Failure | 9 | 2015 | 159 | 0.610 |
Why?
|
Hypoglycemic Agents | 1 | 2018 | 176 | 0.610 |
Why?
|
Medicare | 1 | 2018 | 186 | 0.600 |
Why?
|
Nervous System Neoplasms | 1 | 2017 | 8 | 0.600 |
Why?
|
Disease-Free Survival | 10 | 2018 | 281 | 0.590 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2017 | 32 | 0.580 |
Why?
|
Cerebellar Neoplasms | 2 | 2019 | 11 | 0.560 |
Why?
|
Brain Edema | 2 | 2014 | 16 | 0.540 |
Why?
|
Brain | 7 | 2018 | 930 | 0.540 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2012 | 28 | 0.540 |
Why?
|
Benzhydryl Compounds | 1 | 2015 | 7 | 0.530 |
Why?
|
Ganglioglioma | 1 | 2015 | 6 | 0.530 |
Why?
|
Adolescent | 10 | 2018 | 3254 | 0.530 |
Why?
|
Central Nervous System Diseases | 1 | 2015 | 11 | 0.530 |
Why?
|
Neurofibromatosis 2 | 1 | 2015 | 5 | 0.520 |
Why?
|
Fatigue | 1 | 2015 | 68 | 0.510 |
Why?
|
Choroid Neoplasms | 2 | 2011 | 3 | 0.500 |
Why?
|
Meningeal Carcinomatosis | 1 | 2014 | 6 | 0.500 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 709 | 0.490 |
Why?
|
Brain Stem Neoplasms | 1 | 2014 | 4 | 0.490 |
Why?
|
Tomography, X-Ray Computed | 4 | 2014 | 871 | 0.480 |
Why?
|
Pain Measurement | 3 | 2014 | 364 | 0.480 |
Why?
|
Carcinoma, Small Cell | 1 | 2013 | 21 | 0.470 |
Why?
|
Smoking | 1 | 2017 | 427 | 0.470 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 142 | 0.470 |
Why?
|
Visual Acuity | 3 | 2014 | 66 | 0.460 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2012 | 3 | 0.440 |
Why?
|
Carcinoma, Basal Cell | 1 | 2012 | 27 | 0.440 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2016 | 464 | 0.430 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2019 | 14 | 0.430 |
Why?
|
Ependymoma | 1 | 2012 | 5 | 0.420 |
Why?
|
Surgery, Computer-Assisted | 1 | 2012 | 56 | 0.420 |
Why?
|
Vision Disorders | 1 | 2011 | 20 | 0.410 |
Why?
|
Collagen Diseases | 1 | 2011 | 5 | 0.410 |
Why?
|
Antineoplastic Agents | 6 | 2018 | 546 | 0.400 |
Why?
|
Time Factors | 6 | 2017 | 2001 | 0.400 |
Why?
|
Tumor Burden | 5 | 2014 | 60 | 0.400 |
Why?
|
Medulloblastoma | 1 | 2010 | 7 | 0.390 |
Why?
|
Vascular Diseases | 1 | 2011 | 61 | 0.380 |
Why?
|
Prospective Studies | 8 | 2019 | 2019 | 0.380 |
Why?
|
Cohort Studies | 5 | 2019 | 1687 | 0.380 |
Why?
|
Radiation Oncology | 1 | 2010 | 10 | 0.380 |
Why?
|
Brachytherapy | 1 | 2010 | 22 | 0.380 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2015 | 76 | 0.380 |
Why?
|
Lymphoma | 1 | 2010 | 36 | 0.370 |
Why?
|
Catheter Ablation | 1 | 2010 | 62 | 0.370 |
Why?
|
Risk Factors | 6 | 2017 | 3531 | 0.350 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2015 | 30 | 0.350 |
Why?
|
Facial Pain | 3 | 2014 | 21 | 0.350 |
Why?
|
Incidence | 3 | 2019 | 1119 | 0.340 |
Why?
|
Intracranial Arteriovenous Malformations | 3 | 2012 | 18 | 0.310 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2018 | 19 | 0.310 |
Why?
|
Neoplasm Staging | 3 | 2015 | 436 | 0.300 |
Why?
|
Radiotherapy, Conformal | 2 | 2018 | 19 | 0.300 |
Why?
|
Central Nervous System Neoplasms | 3 | 2014 | 28 | 0.290 |
Why?
|
Child | 6 | 2015 | 2219 | 0.280 |
Why?
|
Cell Line, Tumor | 9 | 2019 | 680 | 0.270 |
Why?
|
Brain Death | 2 | 2017 | 27 | 0.260 |
Why?
|
Multivariate Analysis | 4 | 2014 | 637 | 0.260 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 298 | 0.240 |
Why?
|
DNA Methylation | 2 | 2015 | 130 | 0.240 |
Why?
|
Cause of Death | 2 | 2015 | 220 | 0.240 |
Why?
|
Quality of Life | 3 | 2019 | 816 | 0.230 |
Why?
|
Carcinoma, Renal Cell | 2 | 2017 | 109 | 0.230 |
Why?
|
Kidney Neoplasms | 2 | 2017 | 192 | 0.210 |
Why?
|
Neuropsychological Tests | 4 | 2019 | 379 | 0.210 |
Why?
|
Electromagnetic Fields | 2 | 2019 | 26 | 0.200 |
Why?
|
Lymphatic Metastasis | 2 | 2018 | 156 | 0.200 |
Why?
|
Radiation Dosage | 2 | 2019 | 72 | 0.200 |
Why?
|
Antigens, Neoplasm | 2 | 2019 | 44 | 0.200 |
Why?
|
Neoplastic Stem Cells | 2 | 2019 | 90 | 0.190 |
Why?
|
Analysis of Variance | 3 | 2017 | 454 | 0.180 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2018 | 249 | 0.180 |
Why?
|
Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
Oligodendroglioma | 1 | 2019 | 2 | 0.170 |
Why?
|
Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
Hemangioblastoma | 1 | 2019 | 4 | 0.170 |
Why?
|
Interleukin-23 Subunit p19 | 1 | 2019 | 10 | 0.170 |
Why?
|
von Hippel-Lindau Disease | 1 | 2019 | 5 | 0.170 |
Why?
|
Calcium Channels, T-Type | 1 | 2019 | 29 | 0.170 |
Why?
|
Recurrence | 3 | 2015 | 235 | 0.170 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2018 | 7 | 0.170 |
Why?
|
RNA, Neoplasm | 1 | 2018 | 20 | 0.170 |
Why?
|
Maximum Tolerated Dose | 1 | 2018 | 56 | 0.170 |
Why?
|
Retreatment | 2 | 2016 | 40 | 0.170 |
Why?
|
Mice | 7 | 2019 | 2368 | 0.170 |
Why?
|
Animals | 11 | 2019 | 7297 | 0.170 |
Why?
|
Biopsy, Fine-Needle | 1 | 2018 | 50 | 0.170 |
Why?
|
Postoperative Period | 1 | 2018 | 91 | 0.170 |
Why?
|
Protons | 1 | 2018 | 23 | 0.170 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2016 | 242 | 0.160 |
Why?
|
Microfilament Proteins | 1 | 2018 | 33 | 0.160 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2018 | 80 | 0.160 |
Why?
|
Microglia | 1 | 2018 | 48 | 0.160 |
Why?
|
Disease Management | 1 | 2019 | 114 | 0.160 |
Why?
|
Neovascularization, Pathologic | 3 | 2016 | 81 | 0.160 |
Why?
|
Exosomes | 1 | 2018 | 38 | 0.160 |
Why?
|
Dacarbazine | 2 | 2016 | 29 | 0.160 |
Why?
|
Glomus Jugulare Tumor | 1 | 2017 | 4 | 0.150 |
Why?
|
Calcium | 1 | 2019 | 296 | 0.150 |
Why?
|
Hearing Tests | 1 | 2017 | 11 | 0.150 |
Why?
|
Double-Blind Method | 2 | 2015 | 501 | 0.150 |
Why?
|
Bone Neoplasms | 1 | 2018 | 104 | 0.150 |
Why?
|
Diffusion Tensor Imaging | 1 | 2016 | 29 | 0.150 |
Why?
|
Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2016 | 2 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2016 | 401 | 0.150 |
Why?
|
Confidence Intervals | 1 | 2017 | 140 | 0.150 |
Why?
|
Sulfides | 1 | 2016 | 24 | 0.150 |
Why?
|
Caprylates | 1 | 2016 | 25 | 0.150 |
Why?
|
Signal Transduction | 3 | 2016 | 666 | 0.140 |
Why?
|
Mice, Nude | 4 | 2018 | 276 | 0.140 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2016 | 53 | 0.140 |
Why?
|
MicroRNAs | 1 | 2018 | 173 | 0.140 |
Why?
|
Survivors | 2 | 2018 | 145 | 0.140 |
Why?
|
Cell Proliferation | 4 | 2019 | 573 | 0.140 |
Why?
|
DNA Modification Methylases | 1 | 2015 | 11 | 0.140 |
Why?
|
DNA Repair Enzymes | 1 | 2015 | 16 | 0.140 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2018 | 179 | 0.130 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 189 | 0.130 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2017 | 15 | 0.130 |
Why?
|
Databases, Factual | 1 | 2017 | 332 | 0.130 |
Why?
|
Sarcoma | 1 | 2016 | 56 | 0.130 |
Why?
|
Hypesthesia | 2 | 2015 | 10 | 0.130 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2015 | 6 | 0.130 |
Why?
|
Carmustine | 1 | 2015 | 8 | 0.130 |
Why?
|
Indans | 1 | 2015 | 25 | 0.130 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 72 | 0.130 |
Why?
|
Stereotaxic Techniques | 1 | 2014 | 23 | 0.130 |
Why?
|
Cyclooxygenase 2 | 1 | 2015 | 50 | 0.130 |
Why?
|
Lung | 1 | 2016 | 233 | 0.130 |
Why?
|
Prevalence | 2 | 2014 | 896 | 0.120 |
Why?
|
Neurosurgical Procedures | 1 | 2015 | 98 | 0.120 |
Why?
|
Piperidines | 1 | 2015 | 125 | 0.120 |
Why?
|
Brain Stem | 1 | 2014 | 18 | 0.120 |
Why?
|
Uveal Neoplasms | 1 | 2014 | 25 | 0.120 |
Why?
|
PPAR alpha | 1 | 2014 | 29 | 0.120 |
Why?
|
Taste | 1 | 2013 | 15 | 0.120 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2013 | 32 | 0.110 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 159 | 0.110 |
Why?
|
Influenza Vaccines | 1 | 2014 | 78 | 0.110 |
Why?
|
Eye Proteins | 1 | 2013 | 33 | 0.110 |
Why?
|
Macular Degeneration | 1 | 2013 | 21 | 0.110 |
Why?
|
Smell | 1 | 2013 | 46 | 0.110 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 45 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2012 | 13 | 0.110 |
Why?
|
Ramipril | 1 | 2012 | 4 | 0.110 |
Why?
|
Receptor, erbB-2 | 1 | 2012 | 45 | 0.110 |
Why?
|
Receptors, Estrogen | 1 | 2012 | 89 | 0.110 |
Why?
|
Regression Analysis | 1 | 2013 | 274 | 0.110 |
Why?
|
Neurilemmoma | 1 | 2012 | 14 | 0.110 |
Why?
|
Liver Neoplasms | 1 | 2014 | 162 | 0.110 |
Why?
|
Radiation Injuries, Experimental | 1 | 2012 | 33 | 0.110 |
Why?
|
Nitrogen Mustard Compounds | 1 | 2012 | 4 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2012 | 20 | 0.100 |
Why?
|
Pain, Postoperative | 1 | 2014 | 174 | 0.100 |
Why?
|
Magnetic Resonance Angiography | 1 | 2011 | 64 | 0.100 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 134 | 0.100 |
Why?
|
Facial Paralysis | 1 | 2011 | 7 | 0.100 |
Why?
|
Hydrocephalus | 1 | 2011 | 13 | 0.100 |
Why?
|
Membrane Proteins | 1 | 2013 | 256 | 0.100 |
Why?
|
Age Factors | 2 | 2013 | 1108 | 0.100 |
Why?
|
Arthritis, Rheumatoid | 1 | 2011 | 33 | 0.100 |
Why?
|
Cerebral Cortex | 1 | 2012 | 141 | 0.100 |
Why?
|
Trigeminal Nerve | 1 | 2010 | 5 | 0.100 |
Why?
|
Craniopharyngioma | 1 | 2010 | 8 | 0.100 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2010 | 37 | 0.100 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 33 | 0.100 |
Why?
|
Pituitary Neoplasms | 1 | 2010 | 17 | 0.100 |
Why?
|
Child, Preschool | 2 | 2012 | 1167 | 0.090 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2011 | 145 | 0.090 |
Why?
|
Cell Membrane | 1 | 2010 | 97 | 0.090 |
Why?
|
United States | 1 | 2018 | 3630 | 0.090 |
Why?
|
Sarcoma, Myeloid | 1 | 2009 | 2 | 0.090 |
Why?
|
Heart Neoplasms | 1 | 2009 | 14 | 0.090 |
Why?
|
Cognition | 1 | 2014 | 526 | 0.090 |
Why?
|
North Carolina | 1 | 2013 | 1423 | 0.090 |
Why?
|
Endothelial Cells | 1 | 2010 | 179 | 0.090 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2009 | 173 | 0.080 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2007 | 2 | 0.080 |
Why?
|
Radiodermatitis | 1 | 2006 | 5 | 0.070 |
Why?
|
Green Fluorescent Proteins | 1 | 2007 | 71 | 0.070 |
Why?
|
Rhabdoid Tumor | 1 | 2006 | 4 | 0.070 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2006 | 48 | 0.070 |
Why?
|
Flow Cytometry | 1 | 2007 | 171 | 0.070 |
Why?
|
Deoxycytidine | 1 | 2006 | 63 | 0.070 |
Why?
|
Cell Separation | 1 | 2007 | 86 | 0.070 |
Why?
|
Neoplasm Transplantation | 2 | 2018 | 76 | 0.070 |
Why?
|
Teratoma | 1 | 2006 | 12 | 0.070 |
Why?
|
Transplantation, Heterologous | 2 | 2018 | 121 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 320 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2019 | 519 | 0.060 |
Why?
|
Blotting, Western | 2 | 2015 | 281 | 0.060 |
Why?
|
Pilot Projects | 2 | 2014 | 469 | 0.060 |
Why?
|
Intracranial Hemorrhages | 2 | 2013 | 31 | 0.050 |
Why?
|
Palliative Care | 2 | 2017 | 47 | 0.050 |
Why?
|
Cerebral Angiography | 2 | 2012 | 51 | 0.050 |
Why?
|
Amygdala | 2 | 1999 | 60 | 0.050 |
Why?
|
Body Weight | 2 | 2014 | 290 | 0.050 |
Why?
|
Hippocampus | 2 | 1999 | 185 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 787 | 0.040 |
Why?
|
HMGA2 Protein | 1 | 2019 | 13 | 0.040 |
Why?
|
Down Syndrome | 1 | 1999 | 7 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2019 | 53 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 57 | 0.040 |
Why?
|
Rats | 2 | 2014 | 1604 | 0.040 |
Why?
|
Limbic System | 1 | 1998 | 13 | 0.040 |
Why?
|
Biometry | 1 | 1998 | 12 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 113 | 0.040 |
Why?
|
Mediastinum | 1 | 2018 | 12 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 160 | 0.040 |
Why?
|
Temporal Lobe | 1 | 1998 | 41 | 0.040 |
Why?
|
Transcriptional Activation | 1 | 2018 | 42 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2018 | 263 | 0.040 |
Why?
|
Down-Regulation | 1 | 2018 | 143 | 0.040 |
Why?
|
Up-Regulation | 1 | 2018 | 183 | 0.040 |
Why?
|
Biopsy | 1 | 2018 | 241 | 0.040 |
Why?
|
Cell Movement | 1 | 2018 | 161 | 0.040 |
Why?
|
Models, Biological | 1 | 2019 | 373 | 0.040 |
Why?
|
Topotecan | 1 | 2016 | 15 | 0.040 |
Why?
|
Observer Variation | 2 | 2011 | 96 | 0.040 |
Why?
|
Stilbenes | 1 | 2016 | 25 | 0.040 |
Why?
|
Dementia | 1 | 1999 | 234 | 0.040 |
Why?
|
Cell Adhesion | 1 | 2016 | 103 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2019 | 980 | 0.030 |
Why?
|
Receptors, CCR7 | 1 | 2015 | 3 | 0.030 |
Why?
|
Immunotherapy | 1 | 2016 | 69 | 0.030 |
Why?
|
Cholinesterase Inhibitors | 1 | 2015 | 29 | 0.030 |
Why?
|
Vaccines, Subunit | 1 | 2014 | 3 | 0.030 |
Why?
|
Poly I-C | 1 | 2014 | 4 | 0.030 |
Why?
|
Polylysine | 1 | 2014 | 5 | 0.030 |
Why?
|
Blood-Brain Barrier | 1 | 2015 | 42 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 493 | 0.030 |
Why?
|
Reoperation | 1 | 2015 | 203 | 0.030 |
Why?
|
Cancer Vaccines | 1 | 2014 | 21 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 155 | 0.030 |
Why?
|
Learning | 1 | 2015 | 76 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 248 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2016 | 720 | 0.030 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2014 | 22 | 0.030 |
Why?
|
Influenza B virus | 1 | 2014 | 20 | 0.030 |
Why?
|
Vision, Low | 1 | 2014 | 3 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2014 | 91 | 0.030 |
Why?
|
Retina | 1 | 2014 | 50 | 0.030 |
Why?
|
Memory | 1 | 2015 | 187 | 0.030 |
Why?
|
Microsomes | 1 | 2013 | 14 | 0.030 |
Why?
|
Endoplasmic Reticulum | 1 | 2013 | 24 | 0.030 |
Why?
|
Genes, Dominant | 1 | 2013 | 26 | 0.030 |
Why?
|
Pain | 1 | 2015 | 282 | 0.030 |
Why?
|
Hela Cells | 1 | 2013 | 78 | 0.030 |
Why?
|
Adenoviridae | 1 | 2013 | 61 | 0.030 |
Why?
|
Spin Labels | 1 | 2012 | 23 | 0.030 |
Why?
|
Inflammation | 1 | 2016 | 507 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2012 | 10 | 0.030 |
Why?
|
Rats, Inbred F344 | 1 | 2012 | 125 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 37 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2014 | 264 | 0.030 |
Why?
|
Radiometry | 1 | 2012 | 39 | 0.030 |
Why?
|
Motor Activity | 1 | 2014 | 310 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2012 | 92 | 0.020 |
Why?
|
Otitis Media | 1 | 2011 | 21 | 0.020 |
Why?
|
Pons | 1 | 2010 | 7 | 0.020 |
Why?
|
Spinal Nerve Roots | 1 | 2010 | 14 | 0.020 |
Why?
|
Ceramides | 1 | 2010 | 9 | 0.020 |
Why?
|
Sphingomyelin Phosphodiesterase | 1 | 2010 | 5 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2010 | 17 | 0.020 |
Why?
|
Mutation | 1 | 2013 | 466 | 0.020 |
Why?
|
Cell Death | 1 | 2010 | 71 | 0.020 |
Why?
|
Medical Records | 1 | 2010 | 68 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2010 | 126 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 532 | 0.020 |
Why?
|
Angiotensin I | 1 | 2012 | 262 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 103 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 293 | 0.020 |
Why?
|
Cell Survival | 1 | 2010 | 272 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 2009 | 65 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2011 | 726 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 196 | 0.020 |
Why?
|
Apoptosis | 1 | 2010 | 337 | 0.020 |
Why?
|
Miniaturization | 1 | 2007 | 5 | 0.020 |
Why?
|
Computer Systems | 1 | 2007 | 12 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2007 | 42 | 0.020 |
Why?
|
Myositis | 1 | 2006 | 10 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2007 | 56 | 0.020 |
Why?
|
Equipment Design | 1 | 2007 | 167 | 0.020 |
Why?
|
Atrophy | 1 | 1999 | 51 | 0.010 |
Why?
|
Entorhinal Cortex | 1 | 1998 | 2 | 0.010 |
Why?
|
Anatomy, Cross-Sectional | 1 | 1998 | 14 | 0.010 |
Why?
|
Comorbidity | 1 | 1999 | 540 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 1999 | 1356 | 0.010 |
Why?
|